- Skin-Related Toxicity of Tyrosine Kinase Inhibitor in Thyroid Cancer
-
Lim DJ
- KMID: 2448976
- Int J Thyroidol.
- 2018 Nov;11(2):82-87.
- doi: 10.11106/ijt.2018.11.2.82
Skin-related toxicity is one of the most important adverse events from multi-target tyrosine kinase inhibitor (MTKI) to treat radioiodine refractory thyroid cancer. As hand foot skin reaction can limit quality... -
- CITED
-
- Close
- SHARE
-
- Close
- Peptide Nucleic Acid Clamping and Direct Sequencing in the Detection of Oncogenic Alterations in Lung Cancer: Systematic Review and Meta-Analysis
-
Song JU, Lee J
- KMID: 2418783
- Yonsei Med J.
- 2018 Mar;59(2):211-218.
- doi: 10.3349/ymj.2018.59.2.211
PURPOSE: Molecular testing in non-small cell lung cancer (NSCLC) aids in identifying oncogenic alterations. The aim of this study was to compare the rates of detection of oncogenic alterations and... -
- CITED
-
- Close
- SHARE
-
- Close
- Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells
-
Pei J, Chu T, Shao M, Teng J, Sha H, Gu A, Li R, Qian J, Mao W, Li Y, Han B
- KMID: 2419116
- Yonsei Med J.
- 2017 May;58(3):581-591.
- doi: 10.3349/ymj.2017.58.3.581
PURPOSE: c-Met and its ligand, hepatocyte growth factor (HGF), play a critical role in oncogenesis and metastatic progression. The aim of this study was to identify inhibited enzymogram and to... -
- CITED
-
- Close
- SHARE
-
- Close
- Concomitant AID Expression and BCL7A Loss Associates With Accelerated Phase Progression and Imatinib Resistance in Chronic Myeloid Leukemia
-
Yu N, Shin S, Choi JR, Kim Y, Lee KA
- KMID: 2373641
- Ann Lab Med.
- 2017 Mar;37(2):177-179.
- doi: 10.3343/alm.2017.37.2.177
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells
-
Chang H, Sung JH, Moon SU, Kim HS, Kim JW, Lee JS
- KMID: 2374183
- Yonsei Med J.
- 2017 Jan;58(1):9-18.
- doi: 10.3349/ymj.2017.58.1.9
PURPOSE: Rearrangement of the proto-oncogene rearranged during transfection (RET) has been newly identified potential driver mutation in lung adenocarcinoma. Clinically available tyrosine kinase inhibitors (TKIs) target RET kinase activity, which... -
- CITED
-
- Close
- SHARE
-
- Close
- Angiotensin II Modulates p130Cas of Podocytes by the Suppression of AMP-Activated Protein Kinase
-
Ha TS, Park HY, Seong SB, Ahn HY
- KMID: 2363691
- J Korean Med Sci.
- 2016 Apr;31(4):535-541.
- doi: 10.3346/jkms.2016.31.4.535
Angiotensin II (Ang II) induces the pathological process of vascular structures, including renal glomeruli by hemodynamic and nonhemodynamic direct effects. In kidneys, Ang II plays an important role in the... -
- CITED
-
- Close
- SHARE
-
- Close
- Anti-Proliferative Effects of Rutin on OLETF Rat Vascular Smooth Muscle Cells Stimulated by Glucose Variability
-
Yu SH, Yu JM, Yoo HJ, Lee SJ, Kang DH, Cho YJ, Kim DM
- KMID: 2374042
- Yonsei Med J.
- 2016 Mar;57(2):373-381.
- doi: 10.3349/ymj.2016.57.2.373
PURPOSE: Proliferation of vascular smooth muscle cells (VSMCs) plays a crucial role in atherosclerosis. Rutin is a major representative of the flavonol subclass of flavonoids and has various pharmacological activities.... -
- CITED
-
- Close
- SHARE
-
- Close
- Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells
-
Kim DS, Na YJ, Kang MH, Yoon SY, Choi CW
- KMID: 2373811
- Korean J Intern Med.
- 2016 Mar;31(2):357-366.
- doi: 10.3904/kjim.2015.024
BACKGROUND/AIMS: The treatment of chronic myeloid leukemia (CML) has achieved impressive success since the development of the Bcr-Abl tyrosine kinase inhibitor, imatinib mesylate. Nevertheless, resistance to imatinib has been observed,... -
- CITED
-
- Close
- SHARE
-
- Close
- Current concepts in the management of rheumatoid arthritis
-
Tanaka Y
- KMID: 2373796
- Korean J Intern Med.
- 2016 Mar;31(2):210-218.
- doi: 10.3904/kjim.2015.137
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by inflammation and joint destruction that causes significant morbidity and mortality. However, the combined use of methotrexate, a synthetic disease-modifying antirheumatic... -
- CITED
-
- Close
- SHARE
-
- Close
- Trends and Patterns of Hepatocellular Carcinoma Treatment in Korea
-
Hong YM, Yoon KT, Cho M, Kang DH, Kim HW, Choi CW, Park SB, Heo J, Woo HY, Lim W
- KMID: 2363501
- J Korean Med Sci.
- 2016 Mar;31(3):403-409.
- doi: 10.3346/jkms.2016.31.3.403
Multiple therapeutic modalities are available for hepatocellular carcinoma (HCC) treatment. We aimed to evaluate the trends for HCC treatment in Korea. Recent trends and patterns in treatment modalities were assessed... -
- CITED
-
- Close
- SHARE
-
- Close
- Concomitance of P-gp/LRP Expression with EGFR Mutations in Exons 19 and 21 in Non-Small Cell Lung Cancers
-
Wei H, Lu W, Li M, Zhang Q, Lu S
- KMID: 2466351
- Yonsei Med J.
- 2016 Jan;57(1):50-57.
- doi: 10.3349/ymj.2016.57.1.50
PURPOSE: Traditional chemotherapy is the main adjuvant therapy for the treatment of non-small cell lung cancer (NSCLC). However, the emergence of multi-drug resistance (MDR) has greatly restricted the curative effect... -
- CITED
-
- Close
- SHARE
-
- Close
- Angiotensin III increases monocyte chemoattractant protein-1 expression in cultured human proximal tubular epithelial cells
-
Kim HW, Kim YO, Yoon SA, Han JS, Chun HB, Kim YS
- KMID: 2373780
- Korean J Intern Med.
- 2016 Jan;31(1):116-124.
- doi: 10.3904/kjim.2016.31.1.116
BACKGROUND/AIMS: We investigated whether angiotensin III (Ang III) is involved in monocyte recruitment through regulation of the chemokine monocyte chemoattractant protein-1 (MCP-1) in cultured human proximal tubular epithelial cells (HK-2... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
-
Cho KM, Keam B, Kim TM, Lee SH, Kim DW, Heo DS
- KMID: 2381594
- Korean J Intern Med.
- 2015 Nov;30(6):891-898.
- doi: 10.3904/kjim.2015.30.6.891
BACKGROUND/AIMS: The purpose of this study was to identify predictive factors for erlotinib treatment in non-small cell lung cancer (NSCLC) patients following gefitinib failure. METHODS: Forty-five patients with NSCLC who were... -
- CITED
-
- Close
- SHARE
-
- Close
- Guidelines for the management of myeloproliferative neoplasms
-
Choi CW, Bang SM, Jang S, Jung CW, Kim HJ, Kim HY, Kim SJ, Kim YK, Park J, Won JH
- KMID: 2381581
- Korean J Intern Med.
- 2015 Nov;30(6):771-788.
- doi: 10.3904/kjim.2015.30.6.771
Polycythemia vera, essential thrombocythemia, and primary myelofibrosis are collectively known as 'Philadelphia-negative classical myeloproliferative neoplasms (MPNs).' The discovery of new genetic aberrations such as Janus kinase 2 (JAK2) have enhanced... -
- CITED
-
- Close
- SHARE
-
- Close
- Recent Advances in Palliative Chemotherapy for Unresectable Pancreatic Cancer
-
Ryu JK
- KMID: 2373330
- Korean J Gastroenterol.
- 2015 Sep;66(3):150-153.
- doi: 10.4166/kjg.2015.66.3.150
Pancreatic adenocarcinoma is one of the fatalist malignancies. A large proportion of patients are diagnosed with unresectable stage pancreatic cancer at the time of presentation. Gemcitabine is a standard chemotherapeutic... -
- CITED
-
- Close
- SHARE
-
- Close
- Imatinib mesylate-induced interstitial lung disease in a patient with prior history of Mycobacterium tuberculosis infection
-
Lee NR, Jang JW, Kim HS, Yhim HY
- KMID: 2366019
- Korean J Intern Med.
- 2015 Jul;30(4):550-553.
- doi: 10.3904/kjim.2015.30.4.550
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis
-
Woo HY, Heo J
- KMID: 2164360
- Clin Mol Hepatol.
- 2015 Jun;21(2):115-121.
- doi: 10.3350/cmh.2015.21.2.115
Despite advances in the treatment of hepatocellular carcinoma (HCC), managing HCC with portal vein thrombosis (PVT) remains challenging. PVT is present in 10-40% of HCC cases at the time of... -
- CITED
-
- Close
- SHARE
-
- Close
- The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer
-
Lee JK, Kim DW, Keam B, Kim TM, Lee SH, Kim YJ, Heo DS
- KMID: 2132796
- Cancer Res Treat.
- 2015 Apr;47(2):182-188.
- doi: 10.4143/crt.2013.227
PURPOSE: To investigate the impact of targeted treatment on direct medical costs of patients with advanced non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Medical records of 108 stage IIIB/IV NSCLC... -
- CITED
-
- Close
- SHARE
-
- Close
- Interferon treatment for Japanese patients with favorable-risk metastatic renal cell carcinoma in the era of targeted therapy
-
Sazuka T, Nihei N, Nakamura K, Sakamoto S, Fukasawa S, Komaru A, Ueda T, Igarashi T, Ichikawa T
- KMID: 2133288
- Korean J Urol.
- 2015 Mar;56(3):205-211.
- doi: 10.4111/kju.2015.56.3.205
PURPOSE: Single-agent interferon (IFN) is no longer regarded as a standard option for first-line systemic treatment of metastatic renal cell carcinoma (RCC) in Western countries. However, some patients with favorable-risk... -
- CITED
-
- Close
- SHARE
-
- Close
- beta-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells
-
Yi YW, Kang HJ, Bae EJ, Oh S, Seong YS, Bae I
- KMID: 2155408
- Exp Mol Med.
- 2015 Feb;47(2):e143.
- doi: 10.1038/emm.2014.127
An F-box protein, beta-TrCP recognizes substrate proteins and destabilizes them through ubiquitin-dependent proteolysis. It regulates the stability of diverse proteins and functions as either a tumor suppressor or an oncogene.... -
- CITED
-
- Close
- SHARE
-
- Close
